Skip to main content

Remote Job Finders (RJF)

Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

The recent FDA approval of Fayuvi for a rare, childhood neurodegenerative disease was “particularly special” for Ultragenyx CEO Emil Kakkis. It could also, along with an August nod for another gene therapy, help offset recent challenges brought on by two asset failures.

6 immunology targets to sustain a mammoth I&I market

Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and Sanofi and Regeneron’s Dupixent.

After COVID, biomanufacturing tackles preparedness and commercialization challenges

Manufacturers are redesigning their processes to balance both better future emergency vaccine mobilization and the more demanding work of maintaining flexible, commercially viable manufacturing networks.

Nektar prevails in legal battle with Lilly over broken rezpeg partnership

Nektar Therapeutics has been awarded $90 million in damages after a jury sided with the biotech, which had accused Big Pharma Eli Lilly of “botching” an analysis of their formerly partnered autoimmune drug.

FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’

FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”
Scroll to top